newsfilter
← Latest News
Business Wire·

iECURE Presents Preliminary Clinical Data from Ongoing Clinical Trial of ECUR-506 in Ornithine Transcarbamylase Deficiency at the ASGCT Annual Meeting

Preliminary data from participants enrolled in three dose cohorts (n=7) demonstrate that 71% of participants experienced no hyperammonemic crises (HACs) following ECUR-506 treatment, as of the April 20, 2026 data